Condition: Malignant Melanoma · Sponsor: Inge Marie Svane
This clinical trial is to clarify whether treatment with a checkpoint inhibitor alone (pembrolizumab) or two in combination (ipilimumab and nivolumab), results in clinical benefit for MM patients with brain metastases and in need of steroid treatment. Patients will be treated in four arms depending on steroid dose level at inclusion (\> 10 \< 25 mg prednisolone or \> 25 mg prednisolone) and treatment (pembrolizumab alone or the combination of ipilimumab and nivolumab).
This description comes directly from the study's public registry record.
Inge M Svane, Professor · 004538683868 · inge.marie.svane@regionh.dk
Troels H Borch, PhD · 004538683868 · troels.holz.borch@regionh.dk
Always discuss trial participation with your own doctor first.
| Herlev Universityhospital | Herlev, Capital Region, Denmark | Recruiting |
| Aarhus Universityhospital | Aarhus, Midt, Denmark | Not Yet Recruiting |
| Odense Universityhospital | Odense, Syd, Denmark | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03563729